Page Two - Dr. William Gartland 
Fourth, the proposals ignore the well-established practice of inter-species 
applications of single-gene polypeptide products, arguably analogous to transfer 
of the gene itself. These applications include, for example, the administration 
to human patients of bovine and porcine insulin and salmon calcitonin. Note 
also that human patients have long been the recipient of porcine cardiac valves, 
and of complex secondary metabolites of microbes, e.g., antibiotics. In 
addition, the use of various analogues of naturally-occurring molecules, such as 
fertility and growth hormones and lymphokines , has established the use of "gene 
products" that do not exist in any species in nature. 
i Fifth, the proposed prohibitions would prevent optimal pre-clinical testing of 
the products and procedures intended for clinical trials of human gene therapy. 
; The outcome would be that these clinical trials would be more hazardous, less 
likely to succeed, and, inevitably, delayed. This would represent certain 
detriment to patients afflicted with genetic disorders amenable to gene 
therapy. 
In summary, we urge the RAC to consider seriously the above objections to the 
proposals submitted by the Foundation on Economic Trends, and to reject those 
Sincerely yours. 
Centers for Disease Control 
Health Administration 
Administration 
[ 567 ] 
